<DOC>
	<DOCNO>NCT02305758</DOCNO>
	<brief_summary>This study seek evaluate efficacy tolerability veliparib combination FOLFIRI +/- bevacizumab previously untreated , metastatic adenocarcinoma colon rectum . FOLFIRI chemotherapy regimen fluorouracil , leucovorin irinotecan . This blind study Investigator Subject blind AbbVie unblinded .</brief_summary>
	<brief_title>Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With Without Bevacizumab Previously Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Histologically cytologically confirm metastatic adenocarcinoma colon rectum At least 1 unresectable lesion CT ( Computerized Tomography ) scan measurable defined RECIST , Version 1.1 ECOG ( Eastern Cooperative Oncology Group ) performance score 0 1 Adequate hematologic , renal hepatic function Prior anticancer treatment metastatic colorectal cancer Prior exposure PARP ( poly ADPribose polymerase ) inhibitors The last course adjuvant neoadjuvant chemotherapy must end &gt; 12 month prior colorectal cancer recurrence Any clinically significant uncontrolled major medical condition Participant pregnant lactate Any medical condition , opinion study Investigator , place participant unacceptably high risk toxicity For receive bevacizumab , standard medical exclusionary condition apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>fluorouracil</keyword>
	<keyword>irinotecan</keyword>
	<keyword>colon cancer</keyword>
	<keyword>veliparib</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>previously untreated</keyword>
	<keyword>ABT-888</keyword>
	<keyword>first line</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>5-FU</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>leucovorin</keyword>
</DOC>